Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
John Cavanagh
North Carolina State University Raleigh, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Agile Sciences, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Agile Sciences, Inc. is developing compounds for the dispersion of bacterial biofilms in agricultural, industrial, and medical applications. Dr. Cavanaugh is co-founder and serves on the Board of Directors, but receives no financial compensation from the company. The company is privately held and there is currently no external valuation.
Current NIH grant abstract states that the investigators "...will elucidate the mechanism of action for protein signaling cascades involved in the transition state and in biofilm formation. In addition we will further develop powerful new, non-toxic, small molecules that have been shown to both eradicate insidious pathogenic biofilms and to re-sensitize resistant bacteria to conventional antibiotics."
NMR Studies of Bacterial Regulatory Proteins
There is decreasing investment in antibiotic development because of the rapid increase in resistance to current antibiotics. It is not surprising that no on wants to develop new therapeutics that they believe will soon be useless. Such multi-drug resistance (MDR) will soon result in a worldwide infectious disease crisis. Here, we are addressing the MDR issue in two ways. First, by elucidating the detailed mechanisms by which pathogenic bacteria protect themselves - resulting in pathogenic infection, persistence and transmission. Second, by developing small molecule adjuvants that overcome these bacterial resistance traits such that MDR bacteria become susceptible to current antibiotics once again.
Filed on December 01, 2015.
Tell us what you know about John Cavanagh's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.